Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Tocilizumab for systemic sclerosis: implications for future trials

Systemic sclerosis is a chronic autoimmune disease that causes high morbidity and increases mortality. Although treatments have become available for some manifestations such as pulmonary arterial hypertension, there is still no approved therapy for fibrotic manifestations and the overall course of disease.1 However, following findings about the pathogenesis of fibrotic diseases, several new targeted therapies are being tested in clinical studies.2,3

email